Category - Developments

Aimmune Therapeutics (NASDAQ:AIMT) reported new data from a Phase 3 study of AR101, which delivers a daily dose of peanut protein, as a treatment to reduce the frequency and severity of allergic reactions to peanuts...

ObsEva (NASDAQ:OBSV) completed patient recruitment for its Phase 3 trial of nolasiban for the improvement of rates of pregnancy and live birth in patients undergoing assisted reproduction technology or in-vitro...

Genocea Biosciences (NASDAQ:GNCA) presented positive Phase 1/2a data regarding its neoantigen vaccine candidate, GEN-009, at the American Society of Clinical Oncology annual meeting. GEN-009 is a personalized cancer...

Proteostasis Therapeutics’ (NASDAQ: PTI) PTI-428 has been granted orphan drug designation by the European Medicines Agency (EMA) for the treatment of cystic fibrosis (CF). CF is caused by a mutation in cystic fibrosis...

Verona Pharma (NASDAQ:VRNA) initiated a Phase 2 trial of its metered-dose inhaler (MDI) formulation of ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Ensifentrine inhibits...

Titan Pharmaceuticals (NASDAQ:TTNP) signed a pharmacy services agreement with Southside Specialty Pharmacy, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan’s unique maintenance...

ILJIN SNT, a founding shareholder of Aurinia Pharmaceuticals (NASDAQ:AUPH, TSX:AUP), has filed a dissident proxy circular, nominating three individuals for election as directors at Aurinia’s AGM scheduled for June 26...

Zenabis Global (TSX:ZENA) received an industrial hemp production license from Health Canada. “This is the second cultivation license we have received from Health Canada this year, and is another important step...

iBio (NYSE AMERICAN:IBIO) introduced new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other biologics. Designed for clients with preclinical and...

Epizyme (NASDAQ:EPZM) submitted an NDA to the FDA for tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma. Epithelioid sarcoma is a very rare soft tissue sarcoma. Tazemetostat is a small...